1. Introduction {#sec1-cancers-11-01589}
===============

The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was introduced in 2018 \[[@B1-cancers-11-01589]\] following a successful wave of organ specific reporting systems \[[@B2-cancers-11-01589]\]. The initial internet survey among cytopathologists demonstrated strong support for the new classification system \[[@B3-cancers-11-01589]\]. The goal of the MSRSGC was to develop a practical, evidence-based, user-friendly, and internationally accepted classification system. The system includes characterization and management algorithms for each category \[[@B1-cancers-11-01589],[@B4-cancers-11-01589]\]. Recently, the clinicians endorsed the routine use of the MSRSGC \[[@B5-cancers-11-01589]\].

Salivary gland tumors are one of the most heterogeneous groups of neoplasms with cytopathological features overlapping among the entities. Due to those facts, salivary gland cytopathology is one of the most challenging areas of cytology \[[@B6-cancers-11-01589]\]. Nevertheless, the effectiveness of salivary gland fine needle aspirations (FNA) was shown, as follows: sensitivity 86%, specificity 92%, and diagnostic accuracy 90% \[[@B7-cancers-11-01589]\]. A recent meta-analysis of 16 456 cases from 92 studies confirmed that FNA as a useful method in the salivary gland diagnostics. Furthermore, the retrospective application of the MSRSGC showed an increase in the FNA reliability and reproducibility \[[@B8-cancers-11-01589]\].

The aim of the present study was to analyze salivary gland FNA diagnostics after the implementation of the MSRSGC in the practice of a tertiary care center serving a university hospital, regional hospitals, community health care centers, and private practices.

2. Results {#sec2-cancers-11-01589}
==========

During a one-year-period, 183 salivary gland FNA samples were diagnosed from 138 patients, consisting of 64 (46.4%) males and 74 (53.6%) females. [Table 1](#cancers-11-01589-t001){ref-type="table"} shows the clinical characteristics of the cases in each diagnostic category ([Table 1](#cancers-11-01589-t001){ref-type="table"}). The average age was higher in those who did not have surgical follow-up than those who did. Additionally, the average age was higher in those who had received malignant cytological diagnoses. Lesions with benign cytological diagnoses were bigger in cases with surgical follow-up (average of 2.3 cm vs. 2.0 cm), but lesions with malignant cytological diagnoses were smaller in cases with surgical follow-up (1.5 cm vs. 2.8 cm). In the present study, 153 (83.6%) samples were from the parotid gland, 25 (13.7%) were from the submandibular gland, and five were from other areas: four from parotid lymph nodes and one from the parotid gland area.

A repeat FNA was taken twice in 29 (21.0%) patients, FNA was taken three times in six (4.3%) patients, and FNA was taken four times in two (1.4%) patients. Among all 37 patients with repeat FNA, the 1^st^ FNA was 23× Non-Diagnostic, 8× Atypia of Undetermined Significance (AUS), 4× Neoplasm of Uncertain Malignant Potential (SUMP), in one case Benign Neoplasm and in one case Suspicious for Malignancy. Out of these 37 patients with repeated FNAs, the cytopathological diagnosis changed in 15 (40.5%) cases: in nine cases from Non-Diagnostic category 1× to Non-Neoplastic, 2× to Atypia of Undetermined Significance (AUS), 3× to Benign Neoplasm, 2× to Neoplasm of Uncertain Malignant Potential (SUMP), and 1× to Malignant Neoplasm. In six cases, the cytopathological diagnosis changed from Atypia of Undetermined Significance (AUS) category 3× to Non-Diagnostic and 3× to Neoplasm of Uncertain Malignant Potential (SUMP).

In 90 (49%) FNA cases corresponding to 70 patients, histological follow-up was available, and [Table 2](#cancers-11-01589-t002){ref-type="table"} shows all histological findings according to MSRSGC categories ([Table 2](#cancers-11-01589-t002){ref-type="table"}). In histologically confirmed cases, 50 cases belonged to benign MSRSGC categories (Non-Neoplastic, Atypia of Undetermined Significance, Benign Neoplasm and Neoplasm of Uncertain Malignant Potential). The cytological diagnosis was true-negative in 45 of 90 cases and false-negative in five of 90 cases. In Neoplasm of Uncertain Malignant Potential (SUMP) category, three of 12 (25.0%) cases turned out to be malignant. All three patients were given cytological diagnoses cellular pleomorphic adenoma, but turned out to be carcinoma ex pleomorphic adenoma in histopathology. One out of two non-SUMP false-negative cases was diagnosed as reactive changes on cytology and was categorized into Non-Neoplastic category, but turned out to be extranodal marginal zone B-cell lymphoma of MALT type. The other non-SUMP false-negative case was given a cytological diagnosis as AUS, but it was reported as adenoid cystic carcinoma on histology.

There were nine out of 90 (10%) cases that belonged to the category defined as malignant (Suspicious for Malignancy and Malignant Neoplasm) and all of them turned out to be true-positive cytological diagnoses and none of them were false-positively diagnosed.

Thirty-one (34.4%) of FNA sample cases belonged to the Non-Diagnostic category and 11 of 31 (35.4%) cases turned out to be benign neoplasm and two (6.5%) cases turned out to be malignant neoplasms (extranodal marginal zone B-cell lymphoma of MALT type and carcinoma ex pleomorphic adenoma).

Evaluation of MSRSGC was conducted both patient and sample based for the cases that had histopathological follow-up, as shown in [Table 3](#cancers-11-01589-t003){ref-type="table"} ([Table 3](#cancers-11-01589-t003){ref-type="table"}). When reviewing the results patient based, sensitivity and specificity were 61.5% and 100%, respectively. The diagnostic accuracy of FNA for differentiating between benign and malignant disease was 90.9%. In the sample based evaluation, a slightly higher sensitivity (64.3%) and accuracy (91.5%) were observed. With both evaluation perspectives, the positive predictive value was 100%. The negative predictive values were in the patient based and in the sample based evaluation 89.4% and 90.0%, respectively. The results were also separately calculated for the parotid gland and the submandibular gland. In the comparison between lesions in the parotid gland and the submandibular gland, respectively, the accuracy was 94.0% vs. 71.4%; sensitivity 66.7% vs. 50.0%; and, specificity 100% in both.

Among all FNAs with histological follow-up, 22 out of 90 cases (24.4%) were non-neoplastic lesions, whereas 68 lesions (75.6%) were neoplastic and 16 lesions (17.8%) were malignant. The risk of neoplasm, the risk of malignancy, and the overall risk of malignancy were calculated for each MSRSGC category ([Table 3](#cancers-11-01589-t003){ref-type="table"}) and compared with other MSRSGC studies \[[@B8-cancers-11-01589],[@B9-cancers-11-01589],[@B10-cancers-11-01589],[@B11-cancers-11-01589],[@B12-cancers-11-01589],[@B13-cancers-11-01589],[@B14-cancers-11-01589],[@B15-cancers-11-01589],[@B16-cancers-11-01589],[@B17-cancers-11-01589],[@B18-cancers-11-01589],[@B19-cancers-11-01589],[@B20-cancers-11-01589],[@B21-cancers-11-01589],[@B22-cancers-11-01589],[@B23-cancers-11-01589],[@B24-cancers-11-01589],[@B25-cancers-11-01589],[@B26-cancers-11-01589]\] and MSRSGC estimated ROMs ([Table 4](#cancers-11-01589-t004){ref-type="table"}).

3. Discussion {#sec3-cancers-11-01589}
=============

The one-year-experience with MSRSGC revealed the diagnostic accuracy of FNA for differentiating between benign and malignant disease to be 90.9%. In a detailed analysis, patient vs. sample based analyses comparison showed slightly higher values in samples based analysis due to the increased amount of true positive and true negative cases in the sample based evaluation. Sensitivity was: 61.5% vs. 64.3%, specificity: 100% vs. 100%, PPV: 100% vs. 100%, and NPV: 89.4% vs. 90.0%, respectively. The lesions with well-established cytopathological features, such as pleomorphic adenoma and Warthin's tumor, which are the most common salivary gland tumors, were also well represented in our cohort (16 cases of pleomorphic adenoma and 18 cases of Warthin´s tumor) and attributed to high accuracy \[[@B6-cancers-11-01589]\]. In the 19 retrospective studies and meta-analyses that are summarized in [Table 4](#cancers-11-01589-t004){ref-type="table"} ([Table 4](#cancers-11-01589-t004){ref-type="table"}), the overall accuracy was 93.2%, the sensitivity 82.9%, the specificity 95.1%, the PPV 92.0%, and the NPV 92.1%.

As previously noticed, the diagnostic accuracy varies among salivary gland locations \[[@B6-cancers-11-01589]\]. Despite the fact that the parotid glands are the main targets of both benign and malignant neoplasms, 10--15% of all salivary gland tumors affect submandibular glands with 50% of these being malignant. In the presented institutional MSRSGC analysis, accuracy was 94.0% for parotid glands vs. 71.4% for submandibular glands, sensitivity: 66.7% vs. 50.0%, specificity: 100% vs. 100%, PPV: 100% vs. 100%, and NPV: 93.2% vs. 60.0%, respectively. Nevertheless, recently, Maleki et al. showed submandibular gland ROMs of different MSRSGC categories being similar to those reported for parotid gland cytological specimens \[[@B15-cancers-11-01589]\]. In a Finnish study, six out of 18 malignancies in the submandibular glands were false-negative in FNA (Pap classes 0--2) \[[@B27-cancers-11-01589]\].

If MSRSGC categories are analyzed, all benign categories (one clinical exception in NN category) were below MSRSGC estimated ROMs and all malignant categories were above MSRSGC estimated ROMs ([Table 4](#cancers-11-01589-t004){ref-type="table"}). Interestingly, in contrast to other cytopathological terminologies, MSRSGC also contains a SUMP category specific to salivary glands cytopathology in addition to atypical category (AUS) due to overlapping features among benign and malignant tumors. In our study, the only malignancy that was diagnosed as an AUS case was adenoid cystic carcinoma. In a multi-institutional study, original benign cytological diagnosis was given in 13 out of 46 adenoid cystic carcinoma cases (28.3%) and in MSRSGC reclassification, 23 cases (50%) were diagnosed as SUMP \[[@B28-cancers-11-01589]\].

In comprehensive bi-institutional study by Chowsilpa et al., 65 SUMP cases were retrospectively analyzed \[[@B29-cancers-11-01589]\]. The SUMP category RON was 95.4% in comparison to our study 100% RON. In both studies, pleomorphic adenoma was the most common SUMP benign histopathological correlation. Overall, ROM in SUMP category was 33.8% in Chowsilpa et al. \[[@B29-cancers-11-01589]\] study in comparison to 27.3% in our study. In Chowsilpa et al. study, 60% of SUMP cases revealed unspecific features, 20% were basaloid tumors, and 20% were oncocytic tumors with a lowest ROM of 7.7% in comparison to overall 33.8% \[[@B29-cancers-11-01589]\]. Our study consisted only of two cases of oncocytic SUMP tumors being too small sample amount for conclusions.

False-negative cases were further analyzed to scope diagnostic pitfalls. In our one-year-material, there were five false-negative cases. Extranodal marginal zone B-cell lymphoma of MALT type was falsely diagnosed as reactive lesion in Non-neoplastic MSRSGC category. In a robust review of 6249 cases that was led by the College of American Pathologists, the lymphoma cases featured the highest false-negative rate of 57% \[[@B30-cancers-11-01589]\]. Adenoid cystic carcinoma diagnosed as AUS was discussed in previous paragraph. Three cases of carcinoma ex pleomorphic adenoma were false-negatively diagnosed in the SUMP category. Interestingly, SUMP contained also four other cases of pleomorphic adenoma. Proudly, no cases of false-positive malignancies were reported in the one-year-period.

Unfortunately, we faced high percentage of non-diagnostic cases in our routine practice. In our setting, high percentage of FNAs is taken by a radiologist in training at the beginning of their learning curve shown also by a high percentage of thyroid non-diagnostic FNAs \[[@B31-cancers-11-01589]\]. In histologically confirmed non-diagnostic cases, there were six cystic non-neoplastic lesions and four cystic benign tumors, with both lesions naturally increasing the non-diagnostic rates in cytology \[[@B32-cancers-11-01589],[@B33-cancers-11-01589]\]. In samples-based analysis, two malignancies were originally diagnosed as non-diagnostic, but the diagnostic category increased in repeated FNA. In the literature, ROSE (rapid on site evaluation) also decreased the non-diagnostic rates in salivary gland FNA \[[@B34-cancers-11-01589]\]. According to the Survey on Salivary Gland Cytopathology \[[@B3-cancers-11-01589]\], ROSE is performed by 59% of participants. Retrospective MSRSGC studies and analyses \[[@B8-cancers-11-01589],[@B9-cancers-11-01589],[@B10-cancers-11-01589],[@B11-cancers-11-01589],[@B12-cancers-11-01589],[@B13-cancers-11-01589],[@B14-cancers-11-01589],[@B15-cancers-11-01589],[@B16-cancers-11-01589],[@B17-cancers-11-01589],[@B18-cancers-11-01589],[@B19-cancers-11-01589],[@B20-cancers-11-01589],[@B21-cancers-11-01589],[@B22-cancers-11-01589],[@B23-cancers-11-01589],[@B24-cancers-11-01589],[@B25-cancers-11-01589],[@B26-cancers-11-01589]\] ([Table 4](#cancers-11-01589-t004){ref-type="table"}) did not scope on the role of ROSE and MSRSGC diagnostic accuracy.

Importantly, an increasing amount of salivary gland tumors harbor genetic mutations or rearrangements also detectable in cytological specimens \[[@B35-cancers-11-01589],[@B36-cancers-11-01589],[@B37-cancers-11-01589],[@B38-cancers-11-01589]\] and the widespread use of ancillary techniques can also increase the diagnostic accuracy and reduce SUMP category amount of cases.

4. Materials and Methods {#sec4-cancers-11-01589}
========================

The Department of Pathology, Fimlab Laboratories, Tampere, Finland began the use of the MSRSGC on January 1st, 2018. In an electronic pathology database all salivary gland cytological diagnoses during a one-year-period (January 1st, 2018--December 31st, 2018) were searched for. The follow-up histopathological reports were included for cases wherever they were available until May 22nd, 2019.

The ultrasound-guided fine needle aspirations (FNA) were performed by radiologists with 22G needles. The specimens were alcohol-fixed, cytospin smears were stained with Papanicolaou stain. Cell blocks were routinely made \[[@B39-cancers-11-01589]\]. All of the FNAs were originally diagnosed according to the MSRSGC.

The MSRSGC was critically evaluated by comparing the preoperative FNA diagnoses with the follow-up histopathological diagnoses. The histological follow-up was used as the gold standard to calculate the risk of neoplasm (RON), the risk of malignancy (ROM), and the overall risk of malignancy (OROM) for each diagnostic category in the MSRSGC. The material was analyzed both patient and sample based. In the patient based analysis the most specific and severe cytopathological diagnosis was used.

RON in each diagnostic category was calculated as a ratio between neoplastic cases and all cases with histological follow-up. Similarly, ROM was calculated between malignant cases and all cases with histological follow-up. OROM was calculated between malignant cases and all cases with or without histological follow-up.

Suspicious for Malignancy and Malignant Neoplasm categories were considered as true positive findings, while Non-Neoplastic, Atypia of Undetermined Significance, and Neoplasm (both Benign and Uncertain Malignant Potential) categories were considered as true negative findings. The Non-Diagnostic category was excluded when the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy of FNA for differentiating between benign and malignant disease were determined.

The Ethical Committee of Pirkanmaa Hospital District approved the study (R17174) and informed consent of each individual was not requested. It was conducted according to the Declaration of Helsinki.

5. Conclusions {#sec5-cancers-11-01589}
==============

In conclusions, the presented institutional study provides validation of MSRSGC in salivary gland FNA cytopathological diagnostics in university tertiary care center practice. In our institutional experience, the diagnostic accuracy was 90.9% and ROMs were in agreement with retrospective studies and meta-analyses.
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cancers-11-01589-t001_Table 1

###### 

Milan System for Reporting Salivary Gland Cytopathology (MSRSGC): Clinical Characteristics, Patient Based.

  Cohort                        Surgical Follow-Up           Non-Diagnostic   Non-Neoplastic   AUS              Benign Neoplasm   SUMP             Suspicious for Malignancy   Malignant Neoplasm   Total
  ----------------------------- ---------------------------- ---------------- ---------------- ---------------- ----------------- ---------------- --------------------------- -------------------- ----------------
  No. of FNA Cases (%)          Without surgical follow-up   29 (66%)         5 (83%)          5 (42%)          21 (43%)          5 (31%)          1 (20%)                     2 (33%)              68 (49%)
  With surgical follow-up       15 (34%)                     1 (17%)          7 (58%)          28 (57%)         11 (69%)          4 (80%)          4 (67%)                     70 (51%)             
  Patient Age Average (Range)   Without surgical follow-up   67.4 (26--91)    44.8 (23--69)    62.8 (42--93)    71.3 (45--93)     87.8 (82--90)    66 (66)                     76.5 (61--92)        68.4 (23--93)
  With surgical follow-up       58.3 (20--78)                43 (43)          51.4 (25--69)    49.8 (16--71)    65.4 (24--88)     62.5 (48--79)    66.8 (59--73)               55.6 (16--88)        
  Lesion Size Average (Range)   Without surgical follow-up   1.5 (0.5--5.6)   1.3 (0.9--2.3)   1.5 (0.7--2.2)   2.3 (1.0--3.5)    2.1 (1.0--3.2)   2.5 (2.5)                   3 (2.0--4.0)         1.9 (0.5--5.6)
  With surgical follow-up       2.2 (1.0--4.3)               1.4 (1.4)        2.4 (1.8--3.5)   2.4 (0.9--3.2)   2.1 (1.4--5.2)    1.7 (1.0--3.0)   1.2 (1.0--1.7)              2.1 (0.9--5.2)       

Abbreviations: AUS, Atypia of Undetermined Significance; SUMP, Neoplasm of Uncertain Malignant Potential.

cancers-11-01589-t002_Table 2

###### 

Comparison of MSRSGC Diagnoses with Histopathology, Patient Based.

  MSRSGC Diagnosis            Histopathology Diagnosis                                                                   
  --------------------------- ------------------------------------- ---------------------------------------------------- -----------------------------------------------------------------
  Non-Diagnostic              Cyst (*n* = 6)                        Warthin's tumor (*n* = 3)                            
  Inflammation (*n* = 4)      Oncocytic cystadenoma (*n* = 1)                                                            
                              Lipoma (*n* = 1)                                                                           
  Non-Neoplastic                                                                                                         Extranodal marginal zone B-cell lymphoma of MALT type (*n* = 1)
  AUS                         Cyst (*n* = 2)                        Warthin's tumor (*n* = 2)                            Adenoid cystic carcinoma (*n* = 1)
  Ractive changes (*n* = 1)   Pleomorphic adenoma (*n* = 1)                                                              
  Benign Neoplasm                                                   Warthin's tumor (*n* = 15)                           
                              Pleomorphic adenoma (*n* = 12)                                                             
                              Eccrine spiradenoma (*n* = 1)                                                              
                              Oncocytoma (*n* = 1)                                                                       
  SUMP                                                              Pleomorphic adenoma (*n* = 4)                        Carcinoma ex pleomorphic adenoma (*n* = 3)
                              Basal cell adenoma benign (*n* = 1)                                                        
                              Oncoytic cystadenoma (*n* = 1)                                                             
                              Oncocytoma (*n* = 1)                                                                       
  Suspicious for Malignancy                                                                                              Leiomyosarcoma, metastatic site (*n* = 1)
                                                                    Myoepithelial carcinoma (*n* = 1)                    
                                                                    Salivary duct carcinoma (*n* = 1)                    
                                                                    Squamous cell carcinoma, metastatic site (*n* = 1)   
  Malignant Neoplasm                                                                                                     Carcinoma ex pleomorphic adenoma (*n* = 1)
                                                                    High grade neuroendocrine carcinoma (*n* = 1)        
                                                                    Malignant melanoma, metastatic site (*n* = 1)        
                                                                    Squamous cell carcinoma, metastatic site (*n* = 1)   

Abbreviations: AUS, Atypia of Undetermined Significance; SUMP, Neoplasm of Uncertain Malignant Potential.

cancers-11-01589-t003_Table 3

###### 

Diagnoses According to MSRSGC, Patient and Sample Based.

  Based                       FNA Category     No./Total No. (%)                                                           
  --------------------------- ---------------- ------------------- -------- --------- -------- --------- -------- -------- -------
  Patient Based               Non-Diagnostic   15/44               (34.1)   5/15      (33.3)   0/15      \(0\)    0/44     \(0\)
  Non-Neoplastic              1/6              (16.7)              1/1      \(100\)   1/1      \(100\)   1/6      (16.7)   
  AUS                         7/12             (58.3)              4/7      (57.1)    1/7      (14.3)    1/12     (8.3)    
  Benign Neoplasm             28/49            (57.1)              28/28    \(100\)   0/28     \(0\)     0/49     \(0\)    
  SUMP                        11/16            (68.8)              11/11    \(100\)   3/11     (27.3)    3/16     (18.8)   
  Suspicious for Malignancy   4/5              (80.0)              4/4      \(100\)   4/4      \(100\)   4/5      (80.0)   
  Malignant Neoplasm          4/6              (83.3)              4/4      \(100\)   4/4      \(100\)   4/6      (66.7)   
  Total                       70/138           (50.7)              57/70    (81.4)    13/70    (18.6)    13/138   (9.4)    
  Sample Based                Non-Diagnostic   31/74               (41.9)   13/31     (41.9)   2/31      (6.5)    2/74     (2.7)
  Non-Neoplastic              1/6              (16.7)              1/1      \(100\)   1/1      \(100\)   1/6      (16.7)   
  AUS                         9/20             (45.0)              5/9      (55.6)    1/9      (11.1)    1/20     (5.0)    
  Benign Neoplasm             28/50            (56.0)              28/28    \(100\)   0/28     \(0\)     0/50     \(0\)    
  SUMP                        12/21            (57.1)              12/12    \(100\)   3/12     (25.0)    3/21     (14.3)   
  Suspicious for Malignancy   5/6              (83.3)              5/5      \(100\)   5/5      \(100\)   5/6      (83.3)   
  Malignant Neoplasm          4/6              (66.7)              4/4      \(100\)   4/4      \(100\)   4/6      (66.7)   
  Total                       90/183           (49.2)              68/90    (75.6)    16/90    (17.8)    16/183   (8.7)    

Abbreviations: AUS, Atypia of Undetermined Significance; SUMP, Neoplasm of Uncertain Malignant Potential.

cancers-11-01589-t004_Table 4

###### 

Comparison with Other Studies and MSRSGC Guidelines.

  Study                                                   No. of FNABs    No. of Follow-Ups (%)   Yrs      Risk of Malignant (%)   Accuracy   Sensitivity   Specificity   PPV        NPV                                                                         
  ------------------------------------------------------- --------------- ----------------------- -------- ----------------------- ---------- ------------- ------------- ---------- ---------- ----------- ------ ------ ------ ------- ------- ------- ------- ------
  MSRSGC estimated ROMs (range)                                                                                                    25         10            20            \<5        35         60          \>90                                                 
                                                                                                           (0--67)                 (0--20)    (10--35)      (0--13)       (0--100)   (0--100)   (57--100)                                                        
  Choy 2019 \[[@B9-cancers-11-01589]\]                    376             376                              14                      15         27            29            3          19         88          100    N.D.   N.D.   N.D.    N.D.    N.D.            
  Farahani 2019 (92 studies) \[[@B8-cancers-11-01589]\]   16456           16456                                                    17         8             34            4          42         58          91     N.D.   96.9   95.3    80.5    97.9            
  Hang 2018 (12 studies) \[[@B10-cancers-11-01589]\]      1560            694                     (44.5)   12                      17         10            38            3          41         100         98     N.D.   N.D.   N.D.    N.D.    N.D.            
  Hollyfield 2018) \[[@B11-cancers-11-01589]\]            134             77                      (57.5)   8                       38         17            33            4          33         67          100    N.D.   N.D.   N.D.    N.D.    N.D.            
  Jaiswal 2018) \[[@B12-cancers-11-01589]\]               192             62                      (32.2)   3                       33         7             100           7          100        100         92     86.9   63.2   97.6    92.3    85.4            
  Karuna 2019) \[[@B13-cancers-11-01589]\]                105             76                      (72.4)   2                       0          0             50            2          33         100         93     94.6   85.0   98.1    94.4    94.6            
  Layfield 2018) \[[@B14-cancers-11-01589]\]              164             164                                                      11         5             19            5          40         60          93     95.2   N.D.   N.D.    N.D.    N.D.            
  Maleki 2019) \[[@B15-cancers-11-01589]\]                734             333                     (45.4)   5                       11         8             28            3          42         82          94     N.D.   N.D.   N.D.    N.D.    N.D.            
  Montezuma 2018) \[[@B16-cancers-11-01589]\]             388             104                     (26.8)   7                       25         33            9             2          40         50          100    95.9   62.5   100.0   100.0   95.6            
  Park 2018) \[[@B17-cancers-11-01589]\]                  413             413                              5                       20         7             0             2          26         83          100    N.D.   N.D.   N.D.    N.D.    N.D.            
  Pujani 2019) \[[@B18-cancers-11-01589]\]                150             64                      (42.7)   3                       0          10            50            3          50         100         100    96.9   81.8   100.0   100.0   96.4            
  Rohilla 2017) \[[@B19-cancers-11-01589]\]               631             94                      (14.9)   3                       0          17            100           7          50         N.D.        96     91.4   79.4   98.3    96.4    89.2            
  Sadullahoğlu 2019) \[[@B20-cancers-11-01589]\]          459             129                     (28.1)   4                       22         22            60            0          14         79          90     85.8   95.1   81.0    72.2    96.9            
  Savant 2018) \[[@B21-cancers-11-01589]\]                331             199                     (60.1)   6                       0          0             33            1          41         100         100    N.D.   N.D.   N.D.    N.D.    N.D.            
  Song 2019) \[[@B22-cancers-11-01589]\]                  893             429                     (48.0)   8                       18         14            31            2          47         79          99     N.D.   N.D.   N.D.    N.D.    N.D.            
  Thiryayi 2018) \[[@B23-cancers-11-01589]\]              287             138                     (48.0)   3                       9          2             0             2          27         100         100    99.0   94.6   100.0   100.0   98.8            
  Vallonthaiel 2018) \[[@B24-cancers-11-01589]\]          893             190                     (21.3)   5                       44         8             0             8          44         81          100    N.D.   84.0   96.0    92.0    89.0            
  Viswanathan 2018) \[[@B25-cancers-11-01589]\]           627             373                     (59.5)   6                       7          7             39            5          34         93          92     N.D.   N.D.   N.D.    N.D.    N.D.            
  Wei 2017 (29 studies) \[[@B26-cancers-11-01589]\]       4514            4514                                                     25         10            N.D.          3          38         59          92     N.D.   87.0   85.0    92.0    77.0            
  Overall                                                 29307           24885                   (84.9)   6                       16         11            36            3          40         82          96     93.2   82.9   95.1    92.0    92.1            
  Present Study                                           Patient Based   All                     138      70                      (50.7)     1             0             100        14         0           27     100    100    90.9    61.5    100.0   100.0   89.4
  Parotid                                                 114             57                      (50.0)   1                       0          N.D.          14            0          22         100         100    93.5   62.5   100.0   100.0   92.7            
  Submandibular                                           19              11                      (57.9)   1                       0          100           N.D.          0          100        100         100    71.4   50.0   100.0   100.0   60.0            
  other                                                   5               2                       (40.0)   1                       N.D.       N.D.          N.D.          N.D.       0          N.D.        100    N.D.   N.D.   N.D.    N.D.    N.D.            
  Sample Based                                            All             183                     90       (49.2)                  1          6             100           11         0          25          100    100    91.5   64.3    100.0   100.0   90.0    
  Parotid                                                 153             69                      (45.1)   1                       4          N.D.          11            0          20         100         100    94.0   66.7   100.0   100.0   93.2            
  Submandibular                                           25              15                      (60.0)   1                       14         100           N.D.          0          100        100         100    71.4   50.0   100.0   100.0   60.0            
  other                                                   5               2                       (40.0)   1                       N.D.       N.D.          N.D.          N.D.       0          N.D.        100    N.D.   N.D.   N.D.    N.D.    N.D.            

Abbreviations: ND, Non-Diagnostic; NN, Non-Neoplastic; AUS, Atypia of Undetermined Significance; BM, Benign Neoplasm; SUMP, Neoplasm of Uncertain Malignant Potential; SM, Suspicious for Malignancy; MN, Malignant Neoplasm; PPV, positive predictive value; NPV, negative predictive value; N.D., not determined.
